Literature DB >> 8909805

The p70S6K signalling pathway: a novel signalling system involved in growth regulation.

T C Grammer1, L Cheatham, M M Chou, J Blenis.   

Abstract

This chapter has outlined our current understanding of the regulation of p70S6K activity and its importance for cell growth and proliferation. Although incomplete at the moment, the picture of P70S6K activation reveals novel mechanisms for mitogenic signalling that closely link lipid phosphorylation and protein activation in ways previously unrecognized. Knowledge about the regulation of this signalling pathway is already proving crucial for the medical management of patients. The p70S6K regulating pathways appear to be involved in cell transformation by the polyomavirus. Rapamycin is a strong candidate for use as an immunosuppressant and is currently being tested in clinical trials. Analysis of the activation of the proto-oncogene, akt, demonstrates a possible link of the p70S6K activating pathway to carcinogenesis. Equally exciting is the recent connection between the p70S6K regulating system and IGF2 expression, which may prove crucial for the treatment of IGF2 secreting rhabdomyosarcomas. Certainly, future work will fill in the gaps in our understanding and most likely provide more surprises in the fields of cell biology and molecular oncology.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8909805

Source DB:  PubMed          Journal:  Cancer Surv        ISSN: 0261-2429


  9 in total

Review 1.  Signaling by target of rapamycin proteins in cell growth control.

Authors:  Ken Inoki; Hongjiao Ouyang; Yong Li; Kun-Liang Guan
Journal:  Microbiol Mol Biol Rev       Date:  2005-03       Impact factor: 11.056

2.  Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells.

Authors:  Simrit Parmar; Jessica Smith; Antonella Sassano; Shahab Uddin; Efstratios Katsoulidis; Beata Majchrzak; Suman Kambhampati; Elizabeth A Eklund; Martin S Tallman; Eleanor N Fish; Leonidas C Platanias
Journal:  Blood       Date:  2005-03-24       Impact factor: 22.113

3.  Insulin-like growth factor I-mediated skeletal muscle hypertrophy is characterized by increased mTOR-p70S6K signaling without increased Akt phosphorylation.

Authors:  Yao-Hua Song; Michael Godard; Yangxin Li; Scott R Richmond; Nadia Rosenthal; Patrick Delafontaine
Journal:  J Investig Med       Date:  2005-04       Impact factor: 2.895

4.  A novel role for the cyclin-dependent kinase inhibitor p27(Kip1) in angiotensin II-stimulated vascular smooth muscle cell hypertrophy.

Authors:  R C Braun-Dullaeus; M J Mann; A Ziegler; H E von der Leyen; V J Dzau
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

5.  NPD1 induction of retinal pigment epithelial cell survival involves PI3K/Akt phosphorylation signaling.

Authors:  Natalie A Halapin; Nicolas G Bazan
Journal:  Neurochem Res       Date:  2010-12-07       Impact factor: 3.996

6.  The Src-family tyrosine kinase inhibitor PP1 interferes with the activation of ribosomal protein S6 kinases.

Authors:  O Jameel Shah; Scot R Kimball; Leonard S Jefferson
Journal:  Biochem J       Date:  2002-08-15       Impact factor: 3.857

7.  MiR-128 inhibits tumor growth and angiogenesis by targeting p70S6K1.

Authors:  Zhu-mei Shi; Jing Wang; Zhiping Yan; Yong-ping You; Chong-yong Li; Xu Qian; Yu Yin; Peng Zhao; Ying-ying Wang; Xie-feng Wang; Ming-na Li; Ling-Zhi Liu; Ning Liu; Bing-Hua Jiang
Journal:  PLoS One       Date:  2012-03-19       Impact factor: 3.240

8.  2'-Hydroxyflavanone induced changes in the proteomic profile of breast cancer cells.

Authors:  Lokesh D Nagaprashantha; Jyotsana Singhal; Shireen Chikara; Gabriel Gugiu; David Horne; Sanjay Awasthi; Ravi Salgia; Sharad S Singhal
Journal:  J Proteomics       Date:  2018-09-21       Impact factor: 4.044

9.  Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients.

Authors:  J A van der Hage; L J C M van den Broek; C Legrand; P C Clahsen; C J A Bosch; E C Robanus-Maandag; C J H van de Velde; M J van de Vijver
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.